Acute normal tissue tolerance to 7 day per week accelerated fractionation

Area of Science:

• Radiation Oncology
• Clinical Radiation Therapy

Background:

• Conventional radiation therapy fractionation schedules are standard for cancer treatment.
• Optimizing radiation delivery to improve tumor control while minimizing normal tissue toxicity is an ongoing area of research.

Purpose of the Study:

• To evaluate the clinical tolerability of a 7-day/week accelerated fractionation schedule.
• To assess normal tissue response to accelerated radiation fractionation.

Main Methods:

• Fifty-six treatment sites in 49 patients were irradiated.
• A 7-day/week accelerated fractionation schedule was employed.
• Daily doses ranged from 180 to 200 gray (Gy) in 85% of the sites.

Main Results:

• The 7-day/week accelerated fractionation schedule was found to be clinically tolerable.
• Normal tissue tolerance was analyzed in patients undergoing this regimen.
• A daily dose of 180 gray (Gy) per fraction was observed to be tolerable.

Conclusions:

• A 7-day/week accelerated fractionation schedule is a clinically tolerable option for radiation therapy.
• This accelerated schedule may offer benefits in radiation delivery without compromising normal tissue tolerance at specific dose levels.